Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...

After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans ...

The advent of artificial intelligence (AI) at the US Food and Drug Administration (FDA) is changing the complexion of the regulatory approval process for medical devices.

This Massachusetts-based biopharmaceutical company announced hundreds of layoffs last week. Here's what the CEO said about it ...

Last Monday, the U.S. Department of Health and Human Services (HHS) finalized 10,000 layoffs across federal health agencies, including the National Institutes of Health (NIH), U.S. Food and Drug ...

Adaptimmune Therapeutics plans to drastically cut its workforce, including half of its C-suite, in conjunction with the sale ...

Since Dr. Vinay Prasad’s appointment as a key political voice within FDA, the tone of U.S. biotech policy has shifted from ...

The strategic reprioritization comes after the company hit two major hurdles in the past year, including a clinical hold for ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

BioMarin Pharmaceuticals is one of many biotech companies that’s laid off workers over the past two years. Its office in ...

Companies sometimes miss the mark when it comes to telling employees they’re out of a job. From accidental goodbyes to ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...